C
C. Santos Vivas
Researcher at Carlos III Health Institute
Publications - 5
Citations - 19
C. Santos Vivas is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Colorectal cancer & Internal medicine. The author has an hindex of 1, co-authored 2 publications receiving 12 citations.
Papers
More filters
Journal ArticleDOI
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Joana Vidal,Beatriz Bellosillo,C. Santos Vivas,P. García-Alfonso,Alfredo Carrato,Maria Teresa Cano,R. García-Carbonero,E. Élez,Ferran Losa,B. Massuti,Manuel Valladares-Ayerbes,Jose María Vieitez,Jose Luis Manzano,Daniel Azuara,Javier Gallego,S. Pairet,Gabriel Capellá,R. Salazar,Josep Tabernero,Enrique Aranda,C. Montagut +20 more
TL;DR: No improvement in the selection of patients for anti-EGFR therapy was obtained by adjusting the mutation detection threshold in tissue samples from 5% to 1% MAF, and response rate, progression-free survival, and overall survival were increasingly improved in patients with RAS wild-type, RAS/BRAF wild- type or quadrupleWild-type tumours treated with anti- EGFR.
Journal ArticleDOI
P-118 Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study
C. Santos Vivas,Francesc Salvà,Concepción Fernández-Rodríguez,V. Alonso Orduña,Ferran Losa,David Páez,Joan Vidal,Antonieta Salud,P. Ribera Fernandez,Maria Jose Safont Aguilera,Noelia Tarazona,X. Hernandez-Yagüe,L. Layos Romero,Rocio Garcia-Carbonero,Fernando Rivera,R. Alvarez Gallego,Beatriz Bellosillo,Clara Montagut +17 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of cetuximab plus irinotecan rechallenge in the third-line setting, in comparison to investigator's choice of treatment (excluding anti-EGFR therapy), in patients with RAS, BRAF and EGFR extracellular domain (EGFR-ECD) wild-type mCRC.
Journal ArticleDOI
A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results
G. Chiritescu,Kristoffel R. Dumon,T. Macarulla Mercade,István Láng,C. Santos Vivas,Z. Papai,Jozef Janssens,Koen Hendrickx,M. Pracht,M. Van den Eynde,Julien Taieb,V. Moons,K. Geboes,J.-L. Van Laethem,Richard Greil,A. Cervantes,Philippe Vergauwe,Marc Ferrante,E. Vanderstraeten,M.A. Fridrik,Ewald Wöll,María Luisa Limón,Fernando Rivera,Xavier Sagaert,Sabine Tejpar,E. Van Cutsem +25 more
Journal ArticleDOI
418P Colorectal cancer lung metastases resection and its impact on survival in the oligometastatic setting
J.C. Ruffinelli Rodriguez,Elisabet Guinó,A. Ruiz Valderrama,Gabriel Ibáñez,I. Macía Vidueira,Susana Padrones Sánchez,Arturo Navarro Martín,C. Santos Vivas +7 more
TL;DR: The real benefit of lung metastasectomy and perioperative chemotherapy in survival is still in constant debate and strong prognostic factors are still lacking as mentioned in this paper , however, the authors of this paper present a strong predictor for lung cancer lung metastases.
Journal ArticleDOI
408P Prediction of survival using the G8 scale frailty scale in a prospective series of elderly patients with colon cancer
G. Soler Gonzalez,L. Calonge Raventos,R. Legido-Diaz,C Martínez,Fabricio Torrent,M. Martinez Villacampa,Ferran Losa,C. Santos Vivas,J.C. Ruffinelli Rodriguez,Alex Teulé,M. Gallego,A. Manzana,A. Rios,Silvia Sanchez,Adelaida Piera,Cristina Bermejo Boixareu,R. Salazar,J. Saldaña Cañada +17 more
TL;DR: In this paper , the role of the G8 screening tool in predicting overall survival in elderly colon cancer patients was evaluated, and the authors concluded that G8 is a useful tool to significantly identify patients with colon cancer with a worse prognosis, and it is an independent prognostic factor irrespective of ECOG, age and stage.